roxadustat,durvalumab
fibrogen,astrazeneca,astellas
['gastric', 'matterhorn', 'durva']
 discussant on adj #io to chemo and #io to periop chemo in resectable gastric/gej cancer, benefit appears to be driven by #pd-l1 status, notes matterhorn press release also met primary endpoint of pcr rate (periop chemo + durvalumab) #asco23 
Medical oncologist and researcher in gastrointestinal and genitourinary cancers @CedarsSinai. Hematology/Oncology fellowship @cityofhope